Estrella Immunopharma, Inc. 2Q 2026: Net loss $(2.31M), EPS $(0.05) — 10-Q Summary
Estrella Immunopharma, Inc. reported a net loss of $(2.31M) for the second quarter of 2026, with a loss per share of $(0.05). The company remains pre-revenue, driven by ongoing development and corporate expenses. Key highlights include progress in clinical trials, significant milestones in a …